CRISPR THERAPEUTICS AG (CRSP) Stock Price & Overview
NASDAQ:CRSP • CH0334081137
The current stock price of CRSP is 58.78 USD. Today CRSP is up by 4.04%. In the past month the price increased by 20.6%. In the past year, price increased by 39.55%.
CRSP Key Statistics
- Market Cap
- 5.642B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.41
- Dividend Yield
- N/A
CRSP Stock Performance
CRSP Stock Chart
CRSP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to CRSP. When comparing the yearly performance of all stocks, CRSP is one of the better performing stocks in the market, outperforming 82.62% of all stocks.
CRSP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRSP. No worries on liquidiy or solvency for CRSP as it has an excellent financial health rating, but there are worries on the profitability.
CRSP Earnings
On February 12, 2026 CRSP reported an EPS of -1.37 and a revenue of 864.00K. The company missed EPS expectations (-16.65% surprise) and missed revenue expectations (-80.03% surprise).
CRSP Forecast & Estimates
35 analysts have analysed CRSP and the average price target is 84.28 USD. This implies a price increase of 43.39% is expected in the next year compared to the current price of 58.78.
For the next year, analysts expect an EPS growth of 7.2% and a revenue growth 452.04% for CRSP
CRSP Groups
Sector & Classification
CRSP Financial Highlights
Over the last trailing twelve months CRSP reported a non-GAAP Earnings per Share(EPS) of -5.41. The EPS decreased by -23.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.67% | ||
| ROE | -30.26% | ||
| Debt/Equity | 0 |
CRSP Ownership
CRSP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.33 | 402.17B | ||
| AMGN | AMGEN INC | 16.52 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.59 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.77 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.37 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.71 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.72 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.2 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRSP
Company Profile
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Company Info
IPO: 2016-10-19
CRISPR THERAPEUTICS AG
Baarerstrasse 14
Zug ZUG CH-6300 CH
CEO: Samarth Kulkarni
Employees: 393
Phone: 41415613279
CRISPR THERAPEUTICS AG / CRSP FAQ
Can you describe the business of CRISPR THERAPEUTICS AG?
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
What is the current price of CRSP stock?
The current stock price of CRSP is 58.78 USD. The price increased by 4.04% in the last trading session.
Does CRSP stock pay dividends?
CRSP does not pay a dividend.
How is the ChartMill rating for CRISPR THERAPEUTICS AG?
CRSP has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Is CRISPR THERAPEUTICS AG (CRSP) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CRSP.
Can you provide the number of employees for CRISPR THERAPEUTICS AG?
CRISPR THERAPEUTICS AG (CRSP) currently has 393 employees.
What is the market capitalization of CRSP stock?
CRISPR THERAPEUTICS AG (CRSP) has a market capitalization of 5.64B USD. This makes CRSP a Mid Cap stock.